A patent review of discoidin domain receptor 1 (DDR1) modulators (2014-present)

References

• Vogel WF, Abdulhussein R, Ford CE. Sensing extracellular matrix: an update on discoidin domain receptor function. Cell Signal. 2006;18(8):1108–1116.
   PubMed Web of Science ®Google Scholar
• Vogel W. Discoidin domain receptors: structural relations and functional implications. Faseb J. 1999;13(9001):S77–S82.
   PubMedGoogle Scholar
• Carafoli F, Hohenester E. Collagen recognition and transmembrane signalling by discoidin domain receptors. Biochim Biophys Acta Proteins Proteom. 2013;1834(10):2187–2194.
   PubMed Web of Science ®Google Scholar
• Vogel WF, Aszódi A, Alves F, et al. Discoidin domain receptor 1 tyrosine kinase has an essential role in mammary gland development. Mol Cell Biol. 2001;21(8):2906–2917.
   PubMed Web of Science ®Google Scholar
• Carafoli F, Bihan D, Stathopoulos S, et al. Crystallographic insight into collagen recognition by discoidin domain receptor 2. Structure. 2009;17(12):1573–1581.
   PubMed Web of Science ®Google Scholar
• Dengjel J, Akimov V, Olsen JV, et al. Quantitative proteomic assessment of very early cellular signaling events. Nat Biotechnol. 2007;25(5):566–568.
   PubMed Web of Science ®Google Scholar
• Avraham R, Yarden Y. Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat Rev Mol Cell Biol. 2011;12(2):104–117.
   PubMed Web of Science ®Google Scholar
• Vogel W, Gish GD, Alves F, et al. The discoidin domain receptor tyrosine kinases are activated by collagen. Mol Cell. 1997;1(1):13–23.
   PubMed Web of Science ®Google Scholar
• Leitinger B. Molecular analysis of collagen binding by the human discoidin domain receptors, DDR1 and DDR2: identification of collagen binding sites in DDR2. J Biol Chem. 2003;278(19):16761–16769.
   PubMed Web of Science ®Google Scholar
• Abdulhussein R, Koo DHH, Vogel WF. Identification of disulfide-linked dimers of the receptor tyrosine kinase DDR1. J Biol Chem. 2008;283(18):12026–12033.
   PubMed Web of Science ®Google Scholar
• Moll S, Yasui Y, Abed A, et al. Selective pharmacological inhibition of DDR1 prevents experimentally-induced glomerulonephritis in prevention and therapeutic regime. J Transl Med. 2018;16(1):148.
   PubMedGoogle Scholar
• Guerrot D, Kerroch M, Placier S, et al. Discoidin domain receptor 1 is a major mediator of inflammation and fibrosis in obstructive nephropathy. Am J Pathol. 2011;179(1):83–91.
   PubMed Web of Science ®Google Scholar
• Yeh Y-C, Lin -H-H, Tang M-J. Dichotomy of the function of DDR1 in cells and disease progression. Biochim Biophys Acta, Mol Cell Res. 2019;1866(11):118473.
   PubMed Web of Science ®Google Scholar
• Wang Z, Bian H, Bartual SG, et al. Structure-based design of tetrahydroisoquinoline-7-carboxamides as selective discoidin domain receptor 1 (DDR1) inhibitors. J Med Chem. 2016;59(12):5911–5916.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhang Y, Bartual SG, et al. Tetrahydroisoquinoline-7-carboxamide derivatives as new selective discoidin domain receptor 1 (DDR1) inhibitors. ACS Med Chem Lett. 2017;8(3):327–332.
   PubMed Web of Science ®Google Scholar
• Richter H, Satz AL, Bedoucha M, et al. DNA-encoded library-derived DDR1 inhibitor prevents fibrosis and renal function loss in a genetic mouse model of alport syndrome. ACS Chem Biol. 2019;14(1):37–49.
   PubMed Web of Science ®Google Scholar
• Wang C-Z, Su H-W, Hsu Y-C, et al. A discoidin domain receptor 1/SHP-2 signaling complex inhibits α2β1-integrin–mediated signal transducers and activators of transcription 1/3 activation and cell migration. Mol Biol Cell. 2006;17(6):2839–2852.
   PubMed Web of Science ®Google Scholar
• Xu H, Bihan D, Chang F, et al. Discoidin domain receptors promote α1β1- and α2β1-integrin mediated cell adhesion to collagen by enhancing integrin activation. Plos One. 2012;7(12):e52209.
   PubMed Web of Science ®Google Scholar
• Shintani Y, Fukumoto Y, Chaika N, et al. Collagen I–mediated up-regulation of N-cadherin requires cooperative signals from integrins and discoidin domain receptor 1. J Cell Biol. 2008;180(6):1277.
   PubMed Web of Science ®Google Scholar
• Borza CM, Pozzi A. Discoidin domain receptors in disease. Matrix Biol. 2014;34:185–192.
   PubMed Web of Science ®Google Scholar
• Reger de Moura C, Battistella M, Sohail A, et al. Discoidin domain receptors: a promising target in melanoma. Pigment Cell Melanoma Res. 2019;32(5):697–707.
   PubMed Web of Science ®Google Scholar
• Quan J, Yahata T, Adachi S, et al. Identification of receptor tyrosine kinase, discoidin domain receptor 1 (DDR1), as a potential biomarker for serous ovarian cancer. Int J Mol Sci. 2011;12(2):971–982.
   PubMed Web of Science ®Google Scholar
• Ma Y-S, Wu Z-J, Bai R-Z, et al. DRR1 promotes glioblastoma cell invasion and epithelial-mesenchymal transition via regulating AKT activation. Cancer Lett. 2018;423:86–94.
   PubMed Web of Science ®Google Scholar
• Hur H, Ham I-H, Lee D, et al. Discoidin domain receptor 1 activity drives an aggressive phenotype in gastric carcinoma. BMC Cancer. 2017;17(1):87–98.
   PubMedGoogle Scholar
• Jeitany M, Leroy C, Tosti P, et al. Inhibition of DDR1-BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer. EMBO Mol Med. 2018;10(4):e7918.
   PubMed Web of Science ®Google Scholar
• Miao L, Zhu S, Wang Y, et al. Discoidin domain receptor 1 is associated with poor prognosis of non-small cell lung cancer and promotes cell invasion via epithelial-to-mesenchymal transition. Med Oncol. 2013;30(3):626.
   PubMed Web of Science ®Google Scholar
• Adjei AA. Blocking oncogenic ras signaling for cancer therapy. JNCI. 2001;93(14):1062–1074.
   PubMed Web of Science ®Google Scholar
• Ambrogio C, Nadal E, Villanueva A, et al. KRAS-driven lung adenocarcinoma: combined DDR1/notch inhibition as an effective therapy. ESMO Open. 2016;1(5):e000076–e000076.
   PubMed Web of Science ®Google Scholar
• Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep. 2014;15(12):1243–1253.
   PubMed Web of Science ®Google Scholar
• Multhaupt HAB, Leitinger B, Gullberg D, et al. Extracellular matrix component signaling in cancer. Adv Drug Deliv Rev. 2016;97:28–40.
   PubMed Web of Science ®Google Scholar
• Senthebane DA, Rowe A, Thomford NE, et al. The role of tumor microenvironment in chemoresistance: to survive, keep your enemies closer. Int J Mol Sci. 2017;18(7):1586.
   PubMed Web of Science ®Google Scholar
• Vehlow A, Cordes N. DDR1 (discoidin domain receptor tyrosine kinase 1) drives glioblastoma therapy resistance by modulating autophagy. Autophagy. 2019;15(8):1487–1488.
   PubMed Web of Science ®Google Scholar
• Ambrogio C, Darbo E, Lee SW, et al. A putative role for discoidin domain receptor 1 in cancer chemoresistance. Cell Adh Migr. 2018;12(4):394–397.
   PubMed Web of Science ®Google Scholar
• Moll S, Desmoulière A, Moeller MJ, et al. DDR1 role in fibrosis and its pharmacological targeting. Biochim Biophys Acta, Mol Cell Res. 2019;1866(11):118474.
   PubMed Web of Science ®Google Scholar
• Dorison A, Dussaule JC, Chatziantoniou C. The role of discoidin domain receptor 1 in inflammation, fibrosis and renal disease. Nephron. 2017;137(3):212–220.
   PubMed Web of Science ®Google Scholar
• Flamant M, Placier S, Rodenas A, et al. Discoidin domain receptor 1 null mice are protected against hypertension-induced renal disease. J Am Soc Nephrol. 2006;17(12):3374.
   PubMed Web of Science ®Google Scholar
• Gross O, Girgert R, Beirowski B, et al. Loss of collagen-receptor DDR1 delays renal fibrosis in hereditary type IV collagen disease. Matrix Biol. 2010;29(5):346–356.
   PubMed Web of Science ®Google Scholar
• Avivi-Green C, Singal M, Vogel WF, et al. 1–deficient mice are resistant to bleomycin-induced lung fibrosis. Am J Respir Crit Care Med. 2006;174(4):420–427.
   PubMed Web of Science ®Google Scholar
• Hou G, Vogel W, Bendeck MP. The discoidin domain receptor tyrosine kinase DDR1 in arterial wound repair. J Clin Invest. 2001 Mar 15;107(6):727–735.
   PubMed Web of Science ®Google Scholar
• Franco C, Hou G, Ahmad Pamela J, et al. Discoidin domain receptor 1 (Ddr1) deletion decreases atherosclerosis by accelerating matrix accumulation and reducing inflammation in low-density lipoprotein receptor–deficient mice. Circ Res. 2008;102(10):1202–1211.
   PubMed Web of Science ®Google Scholar
• Franco C, Britto K, Wong E, et al. Discoidin domain receptor 1 on bone marrow–derived cells promotes macrophage accumulation during atherogenesis. Circ Res. 2009;105(11):1141–1148.
   PubMed Web of Science ®Google Scholar
• Ahmad PJ, Trcka D, Xue S, et al. Discoidin domain receptor-1 deficiency attenuates atherosclerotic calcification and smooth muscle cell-mediated mineralization. Am J Pathol. 2009;175(6):2686–2696.
   PubMed Web of Science ®Google Scholar
• Franco C, Ahmad Pamela J, Hou G, et al. Increased cell and matrix accumulation during atherogenesis in mice with vessel wall–specific deletion of discoidin domain receptor 1. Circ Res. 2010;106(11):1775–1783.
   PubMed Web of Science ®Google Scholar
• Tsutsui H, Okimura K, Udagawa S, et al. Urea derivatives and use thereof. WO2017038870 (A1). 2017.
   Google Scholar
• Nishio Y, Yamamoto M, Kubota Y, et al. Urea derivatives and use thereof. WO2017038871 (A1). 2017.
   Google Scholar
• Nishio Y, Kubota Y, Yamamoto M, et al. Urea derivatives and use thereof. WO2017038873 (A1). 2017.
   Google Scholar
• Brekken RA, Ding K, Ren XM, et al. Small-molecule inhibitors targeting discoidin domain receptor 1 and uses thereof. WO2016064970 (A1). 2016.
   Google Scholar
• Zhu D, Huang H, Pinkas DM, et al. 2-amino-2,3-dihydro-1H-indene-5-carboxamide-based discoidin domain receptor 1 (DDR1) inhibitors: design, synthesis, and in vivo antipancreatic cancer efficacy. J Med Chem. 2019;62(16):7431–7444.
   PubMed Web of Science ®Google Scholar
• Murata T, Hara S, Niizuma S, et al. Quinazolinone and isoquinolinone derivative. WO2015060373 (A1). 2015.
   Google Scholar
• Jiang QL, Chen C, Xu XH, et al. 1H-indole derivative and application thereof. CN108276388 (A). 2018.
   Google Scholar
• Chen C, Deng J, Yu X, et al. Identification of novel inhibitors of DDR1 against idiopathic pulmonary fibrosis by integrative transcriptome meta-analysis, computational and experimental screening. Mol Biosyst. 2016;12(5):1540–1551.
   PubMed Web of Science ®Google Scholar
• Jr RA G, Dumelin CE, Keefe AD. DNA-encoded chemistry: enabling the deeper sampling of chemical space. Nat Rev Drug Discov. 2016 Dec 09 online;16:131.
   PubMed Web of Science ®Google Scholar
• Buettelmann B, Kocer B, Kuhn B, et al. Spiroindolinones as DDR1 inhibitors. WO 2017137334 (A1). 2017.
   Google Scholar
• Buettelmann B, Kocer B, Kuhn B, et al. Triaza-spirodecanones as DDR1 inhibitors. WO 2017005583 (A1). 2017.
   Google Scholar
• Mak -K-K, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discov Today. 2019;24(3):773–780.
   PubMed Web of Science ®Google Scholar
• Chan HCS, Shan H, Dahoun T, et al. Advancing drug discovery via artificial intelligence. Trends Pharmacol Sci. 2019;40(8):592–604.
   PubMed Web of Science ®Google Scholar
• Vamathevan J, Clark D, Czodrowski P, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18(6):463–477.
   PubMed Web of Science ®Google Scholar
• Lavecchia A. Deep learning in drug discovery: opportunities, challenges and future prospects. Drug Discov Today. 2019;24(10):2017–2032.
   PubMed Web of Science ®Google Scholar
• Zhavoronkov A, Ivanenkov YA, Aliper A, et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nat Biotechnol. 2019;37(9):1038–1040.
   PubMed Web of Science ®Google Scholar
• Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer. 2006;6(9):714–727.
   PubMed Web of Science ®Google Scholar
• Hansel TT, Kropshofer H, Singer T, et al. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010;9(4):325–338.
   PubMed Web of Science ®Google Scholar
• Smith V, Mccauley A, Vaysberg M, et al. Anti-DDR1 antibodies. WO2014047624 (A1). 2014
   Google Scholar
• MC PÉREZ. Anti-DDR1 internalizing antibodies and their medical use. WO2014140330 (A1). 2014.
   Google Scholar
• Jun HT, Horlick RA, King DJ, et al. Antibodies directed against discoidin domain receptor family, member 1 (DDR1). WO2015116569 (A2). 2015.
   Google Scholar
• Gerg M, Schraeml M, Hillringhaus L, et al. Novel anti-pY520-DDR1 antibodies. WO2018083237 (A1). 2018.
   Google Scholar
• Gerg M, Schraeml M, Hillringhaus L, et al. Novel anti-pY792-DDR1 antibodies. WO2018083238 (A1). 2018.
   Google Scholar
• Gerg M, Schraeml M, Hillringhaus L, et al. Novel anti-pY796-DDR1 antibodies. WO2018083240 (A1). 2018.
   Google Scholar
• Kim H-G, Tan L, Weisberg EL, et al. Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor. ACS Chem Biol. 2013;8:2145–2150.
   PubMed Web of Science ®Google Scholar
• Grither WR, Longmore GD. Inhibition of tumor–microenvironment interaction and tumor invasion by small-molecule allosteric inhibitor of DDR2 extracellular domain. Proc Nat Acad Sci. 2018;115(33):E7786–E7794.
   PubMed Web of Science ®Google Scholar